+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID04538937

Registry Study of Eosinophilia with Lung Involvement and Translational Research to Identify and Study Eosinophils

Led by Medical University Innsbruck · Updated on 2020-09-04

300

Participants Needed

1

Research Sites

469 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a prospective registry study to better understand eosinophilic lung diseases, such as eosinophilic asthma, eosinophilic granulomatosis with polyangiitis EGPA, Samter Triad, hypereosinophilic syndrome HES, and eosinophilic pneumonia. These conditions can affect the lungs alone or be part of systemic diseases, and their causes and treatments are not yet fully understood. The study aims to explore different subtypes of eosinophils and their roles in these respiratory conditions, including the relationship between blood eosinophil levels and organ damage risk. This observational study includes patients who have eosinophilia with respiratory involvement and are diagnosed with the specified diseases. It includes patients switching from doctor-administered injections of the anti-IL5 antibody mepolizumab to self-injection pens. Special attention is given to patients with Samter Triad, monitoring asthma control, nasal polyps, and NSAID intolerance. The study also investigates whether some severe cases represent a clonal lymphoid HES by analyzing chemokines, mutations, and cell markers. Advanced laboratory techniques are used to characterize eosinophil subtypes in patients and healthy controls. Participants will provide consent to join the registry, and their medical data including laboratory tests, lung function, imaging, biopsies, and allergology findings will be collected over time during routine care. Additional blood samples are taken during regular blood draws for research purposes without extra risk. Healthy volunteers also provide blood samples for comparison. The main outcomes include establishing the registry with detailed disease and therapy data over 10 years and identifying eosinophil subtypes in peripheral blood within one year. There are no additional risks beyond standard care for participants.

CONDITIONS

Brief Title

Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils

Research Team

I

Ivan Tancevski, MD

J

Judith Löffler-Ragg

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here